The U.S. Food and Drug Administration (FDA) Thursday authorized a third dose of Pfizer-BioNTech and Moderna COVID vaccines for people with compromised immune systems.
Neither vaccine has yet received full FDA approval, and neither has completed late-stage clinical trials proving a third dose will boost immunity or work against COVID variants.
The amended Emergency Use Authorization allows people who have had an organ transplant, or those with a similar level of weakened immune system, to get an extra COVID vaccine dose.
The FDA did not approve a Johnson & Johnson booster, citing insufficient data.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today voted unanimously to recommend the CDC follow the FDA’s guidance by also approving the third shots for immunocompromised patients.
Thursday’s decision by the FDA “allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19,” Dr. Janet Woodcock, FDA acting commissioner, tweeted Thursday.
“Others who are fully vaccinated are adequately protected & do not need an additional dose of COVID-19 vaccine at this time,” Woodcock said in the tweet. The vulnerable group of patients eligible for the third shot make up less than 3% of U.S. adults, according to Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC).
Israel started administering booster vaccines on July 12, to people 60 or older, and other countries plan to follow. On Aug. 13, Israel expanded the booster vaccination campaign to include people 50 years and older — a revision from the previous age eligibility requirement of 60 years and up.
Yet, Israeli Health Ministry data published Aug. 12 showed 14 Israelis had been infected with COVID a week after receiving a booster shot. Eleven people infected were 60 or older, and two were hospitalized — while the other three received a third dose because they are immunocompromised.
If confirmed in larger samples, the Internal Health Ministry said figures could cast doubt on the effectiveness of the booster shot, which Israel started administering before major health agencies around the world approved it.
The FDA’s authorization came as Biden administration officials and pharmaceutical companies appear increasingly convinced boosters for the broader population will be necessary.
Scientists are divided over the broad use of COVID vaccine boosters among those without underlying problems, as benefits of the boosters remain undetermined.
Officials are scrutinizing data on the vaccines’ durability and discussing when extra shots might need to be administered and which groups might get priority, according to federal officials who spoke on the condition of anonymity.
Those officials told The Washington Post discussions have become increasingly urgent as some studies indicate a waning of the vaccines’ protection over time.
“No vaccine, at least not within this category, is going to have an indefinite amount of protection,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said Thursday on NBC’s “Today” show. “Inevitably, there will be a time when we’ll have to get boosts.”
Safety and efficacy data on boosters lacking
At the end of July, Pfizer and BioNTech announced findings showing four to six months after a second dose, their vaccine’s efficacy dropped to about 84%.
Earlier this month, Moderna said its two-dose vaccine was 93% effective, with efficacy “remaining durable” through six months after the second dose. However, “neutralizing titers will continue to wane and eventually impact vaccine efficacy,” the company said. “Given this intersection, we believe dose 3 booster will likely be necessary prior to the winter season.”
Pfizer CEO Albert Bourla said he is “very, very confident” a booster will increase immunity levels in the vaccinated.
According to Kaiser Health News (KHN), Pfizer has not yet delivered conclusive proof to back up that confidence. The company lacks late-stage clinical trial results to confirm a booster will work against COVID variants, including Delta — which now accounts for 93% of new infections across the U.S.
Pfizer in July announced its global phase 3 trial — which assesses the safety, efficacy and immunogenicity of a third dose — but the trial’s completion date isn’t until 2022. Phase 3 results generally are required before regulatory approval, KHN reported.
“We are confident in this vaccine and the third dose, but you have to remember the vaccine efficacy study is still going on, so we need all the evidence to back up that,” Jerica Pitts, Pfizer’s director of global media relations, said Monday.
Moderna’s clinical trial “designed to assess the safety, reactogenicity and immunogenicity of a delayed vaccine boost” has an estimated primary completion date of May 28, 2023, and study completion date of 2025.
The financial stakes are high for Pfizer, which announced in July it expects to pull in $33.5 billion in COVID vaccine revenue this year.
According to Reuters, Pfizer, along with German partner BioNTech, and Moderna have together locked up COVID vaccine supply agreements worth more than $60 billion in sales, just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.
Analysts forecasted revenue of more than $6.6 billion for Pfizer’s COVID vaccine and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.
Meanwhile, Pfizer recently said if a third dose couldn’t combat the Delta or other variants, the drugmaker is prepared to come up with a “tailor-made” vaccine within 100 days, KHN reported.
All of this has sown a sense of confusion about what exactly will work, and when. The pharmaceutical industry’s rush to recommend boosters for the public is “a little frustrating,” said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and an adviser to the National Institutes of Health and FDA.
Even if a booster is found to be safe, Offit said, the U.S. effort should focus on “vaccinating people who are unvaccinated.” In any case, decisions about boosters do not rest with vaccine makers, he said.
“Pharmaceutical companies aren’t public health agencies, it’s really not theirs to determine when or whether there should be booster dosing,” Offit said. “That is the purview of the CDC.”
It is my sincere desire to provide readers of this site with the best unbiased information available, and a forum where it can be discussed openly, as our Founders intended. But it is not easy nor inexpensive to do so, especially when those who wish to prevent us from making the truth known, attack us without mercy on all fronts on a daily basis. So each time you visit the site, I would ask that you consider the value that you receive and have received from The Burning Platform and the community of which you are a vital part. I can't do it all alone, and I need your help and support to keep it alive. Please consider contributing an amount commensurate to the value that you receive from this site and community, or even by becoming a sustaining supporter through periodic contributions. [Burning Platform LLC - PO Box 1520 Kulpsville, PA 19443] or Paypal
-----------------------------------------------------
To donate via Stripe, click here.
-----------------------------------------------------
Use promo code ILMF2, and save up to 66% on all MyPillow purchases. (The Burning Platform benefits when you use this promo code.)
Look, basically they can approve one hundred million vaccines for one hundred million different diseases and I will not take one of them. This is not the kind of world that we want to live in. A world with all the fun and creativity sucked out of it where we tip toe around all day and night in fear of germs. I say let the sheeple follow Fadouchi and company over the cliff. That is OK by me. The rest of us will go off on our own and create a world worthy of our human love, compassion and genius. Go have your needle point fun leave us the ‘F’ alone. Thank you.
So what happened to: “Follow the Money”? Are the majority of humans just gullible fools?
Yes.
FEAR stocks………..$ Ka-ching $
Moderna stock price up over 500% in the last year alone.
Truthfully, it would be darkly satisfying to short the hell out of this one but given the current lunacy it would be borderline insanity to do so. Would rather sell old sports memorabilia and use the proceeds to buy gold.
Yeah, but the pharmaceutical companies run the CDC – no CDC officials will dare go contrary to the pharmaceutical companies’ wishes, so as not to jeopardize their cushy post-CDC jobs at the pharmaceutical companies. Ditto the FDA and any other gov’t regulatory agency that has any oversight over the pharmaceutical industry.
The pharmaceutical companies also run the medical profession by providing massive funding for medical schools and a gravy train of perqs for doctors in exchange for prescribing their “medications.”
Likewise the telecomms and the FCC. Likewise big Agra & USDA (and EPA). Likewise …….
This is what it is to live in a failed state.
Back I the ‘70s, Alka Seltzer was looking to boost profits. Their product worked well to relieve heartburn. Too well, in fact. Their advertising agency came up with a brilliantly simple campaign that doubled revenues overnight. The over 50 crowd here knows what I’m talking about.
“Plop, plop, fizz, fizz, oh what a relief it is.”
You only need to take one. One works just fine, and did for years. But the ad campaign says take two. So now you do.
We have a flu with a 99.97% survival rate. But the ad campaign said to take a jab. Make that two. No, make it three. No, make it an annual. Better yet, a bi-annual. Woah, there’s the Sigma variant. Better take it monthly. And just like that, Big Pharma goes from a one-time sale to a 12x annual revenue stream.
If it doesn’t kill everyone, anyway.